# iLeukon Therapeutics

Source: https://onco.cc/companies/ileukon-therapeutics/  
OnCo record `ileukon-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

iLeukon Therapeutics makes ILKN421H, an mRNA medicine given into a vein that makes the body produce a modified form of interleukin-2, an immune signal that boosts cancer-killing T cells. It is being tested with pembrolizumab in advanced non-small cell lung cancer.

## Summary

iLeukon Therapeutics, Inc., at 6393 Nancy Ridge Road, San Diego, California, is a clinical-stage company developing interleukin-2 based mRNA therapies for cancer; its website also refers to the company as Cytimm, which co-founder Haining Huang is described as co-founding in February 2020 as a spin-off of ACEA Therapeutics' immuno-oncology division. Its lead product ILKN421H is a lipid nanoparticle mRNA drug, given intravenously, that encodes a fusion of human serum albumin with a non-alpha IL-2 variant that binds IL-2 receptor beta and gamma but not alpha, intended to activate CD8 T cells and NK cells without expanding regulatory T cells. The company says investigator-initiated trials of ILKN421H alone or with pembrolizumab began in 2023 (first in human in August 2023), and its pipeline lists a US IND with a phase 2 protocol for ILKN421H plus pembrolizumab in first-line and post-immunotherapy non-small cell lung cancer (October 2025) and a combination with a CD19 in vivo CAR-T. Its first registered cancer trial, NCT07452224, a phase 2 study of ILKN421H with pembrolizumab in advanced NSCLC, was posted on ClinicalTrials.gov in March 2026. Its chairman, Henry Ji, co-founded Sorrento Therapeutics.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: iLeukon Therapeutics, Inc.; Cytimm Therapeutics
- HQ: San Diego, CA
- Type: biotech
- Website: http://www.ileukon.com/

## Notes

- Founding year not recorded: the website describes a co-founder founding Cytimm Therapeutics in February 2020, but does not state when iLeukon itself was formed or confirm that the two are the same entity.
- The registry contact domain is cytimm.com, which did not serve readable content; the iLeukon website renders with JavaScript and was read from its application code.
- Earlier investigator-initiated trials described by the company were not found in the registry data read.
- No financing round was found; none is recorded.
- Company website read on 29 October 2026.

## Sources

- Official website: http://www.ileukon.com/
- ClinicalTrials.gov: phase 2 trial of ILKN421H plus pembrolizumab in advanced NSCLC (NCT07452224): https://clinicaltrials.gov/study/NCT07452224

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/)
- targets: [IL2RB](https://onco.cc/targets/il2rb/), [IL2RG](https://onco.cc/targets/il2rg/)
- trials: [ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07452224/)

---
JSON: https://onco.cc/api/v1/entities/ileukon-therapeutics.json